Board of Directors


Ronald C. Renaud has served as the President and Chief Executive Officer of Idenix Pharmaceuticals, Inc. since October 2010. Prior to this, Mr. Renaud served as the Chief Financial Officer of Idenix since June 2007 and additionally as Chief Business Officer since June 2010. Mr. Renaud brings a unique mix of skills to this role with his finance experience at public biotechnology companies and on Wall Street, as well as his science background. Prior to joining Idenix, Mr. Renaud served as chief financial officer of Keryx Biopharmaceuticals. In this role he was responsible for the strategic planning and development of the finance function to support the company's growth and its late-stage product candidate development. Prior to his position at Keryx, he spent several years as a senior biotechnology equity analyst for leading investment banks including Bear Stearns, Schwab SoundView and JP Morgan. Additional industry experience includes Mr. Renaud's more than five years at Amgen Inc., where he held positions in clinical research, investor relations and finance.

Mr. Renaud holds a Masters in Business Administration from the Marshall School of Business at the University of Southern California and a Bachelor of Arts from St. Anselm College in Manchester, NH.

Wayne T. Hockmeyer, Ph.D. has served as a director since February 2002. Dr. Hockmeyer founded MedImmune, Inc., a biotechnology company, in April 1988 and served until October 2000 as the chief executive officer of MedImmune. In October 2000, Dr. Hockmeyer relinquished his position as chief executive officer and now serves as chairman of the board of directors, MedImmune, Inc. and president of MedImmune Ventures, Inc., a wholly-owned subsidiary of MedImmune, Inc. Dr. Hockmeyer also serves as a director of Advancis Pharmaceutical Corporation, GenVec, Inc., Tercica, Inc. and TolerRx, Inc. Dr. Hockmeyer was recognized, in 1998, by the University of Florida as a Distinguished Alumnus and in 2002 was awarded a Doctor of Science honoris causa from Purdue University. Dr. Hockmeyer holds a B.S. from Purdue University and a Ph.D. from the University of Florida.

Chair of the Compensation Committee

Thomas R. Hodgson has served as Chairman of the Board since March 2012 and as a director since February 2002. From September 1990 to January 1999, Mr. Hodgson served as the president and chief operating officer of Abbott Laboratories. From 1983 to 1990, Mr. Hodgson served as the president of Abbott International and from 1978 to 1983, Mr. Hodgson served as the president of the Hospital Products Division of Abbott Laboratories. Mr. Hodgson is a director of The St. Paul Travelers Inc. and Intermune, Inc. Mr. Hodgson holds a B.S. from Purdue University, an M.S. from the University of Michigan, an M.B.A. from Harvard Business School and an honorary doctorate degree in engineering awarded by Purdue University.

Member of the Compensation Committee
Recent Stock Transactions by Thomas R. Hodgson
Date Type Shares Traded Price Range
Dec 16, 2009 Buy 10,387 2.12
Dec 15, 2009 Buy 15,000 2.15
Dec 14, 2009 Buy 11,000 2.12
Dec 11, 2009 Buy 8,613 2.08
Dec 10, 2009 Buy 5,000 2.05

Tamar Howson has served as a director since March 2010. Prior to joining JSB-Partners, Ms. Howson was executive vice president of business development at Lexicon Pharmaceuticals where she led the company's partnering and licensing efforts. From 2001 to 2007, Tamar was senior vice president corporate and business development at Bristol Myers Squibb overseeing M&A, licensing and research collaborations across all businesses. In 2000 and 2001, Ms. Howson served as a business development and strategy consultant to biotechnology companies in the United States and in Europe. Ms. Howson worked at SmithKline Beecham from 1991 to 2000, where she was senior vice president and director of business development, responsible for worldwide in-licensing and business development. She also managed SR One, SmithKline Beecham's $100 million venture capital fund. Before joining SmithKline Beecham, Ms. Howson served as vice president, venture investments at Johnson Associates, a venture capital firm, and earlier as director, worldwide business development and licensing for Squibb Corporation. In 1999, Ms. Howson received the Healthcare Businesswomen's Association "Woman of the Year" Award. Ms. Howson currently serves on the board of S*Bio Pte Ltd., a consultant to Pitnago Venture Fund and is a member of the advisory board to Triana Venture Partners. She previously served on the boards of Ariad Pharmaceuticals, SkyPharma, NPS Pharma, Targacept, and HBA. Ms. Howson holds an M.B.A from Columbia University, a M.S. from City College of New York and a B.S. in Chemical Engineering from the Technion in Israel.

Denise Pollard-Knight, Ph.D. has served as a director since May 2003. From January 1999 to March 2004, Dr. Pollard-Knight served as head of Healthcare Private Equity at Nomura International plc, a leading Japanese financial institution. Since April 2004, Dr. Pollard-Knight has served as head of Nomura Phase4 Partners, formerly known as Phase4 Ventures, an affiliate of Nomura International plc. Prior to joining Nomura, Dr. Pollard-Knight was a member of Rothschild Asset Management Ltd., an investment management firm, from January 1997 to January 1999. Dr. Pollard-Knight held several research and development management positions at Amersham-Pharmacia and Fisons plc. In December 2005, Dr. Pollard-Knight became a member of the Board of Trustees of the British Heart Foundation. Dr. Pollard-Knight holds a Ph.D. and BSc (Hons) from the University of Birmingham in England. Dr. Pollard-Knight completed postdoctorate work as a Fulbright Scholar at the University of California, Berkeley.

Anthony has served as a director since December 2012. Previously, Mr. Rosenberg served as a director from June 2009 to March 2012. Mr. Rosenberg is Head, Partnering and Emerging Businesses of Novartis Pharma AG and a member of the Pharma Executive Committee. He joined Sandoz in 1980 in the UK where he held various leadership positions in sales and marketing, business development and strategic planning. In 1994 he moved to Basel, initially as international product manager (Clozaril), and undertook roles of increasing responsibility in Global Marketing, ultimately as Head Global Marketing Primary Care. In 2000 he became Global Head of the Transplant and Immunology Business Unit and in 2005, he was appointed Global Head of Business Development and Licensing. He has overseen many major in-licensing transactions in the respiratory, infectious disease, CNS areas. Tony Rosenberg has a BSc (Biological Sciences) University of Leicester, and an M.Sc (Physiology) University of London.

Charles Rowland has served as a director since June 2013. Mr. Rowland is the Former Vice President and Chief Financial Officer of ViroPharma Incorporated. He has more than 28 years of diversified experience across a broad field of financial areas and accounting, including financial reporting, tax, treasury, and strategic financial planning.  Prior to joining ViroPharma, Mr. Rowland was executive vice president and chief financial officer at Endo Pharmaceuticals and served for a period as co-interim chief executive officer.  Previously, he was senior vice president, chief financial officer for Biovail Pharmacueticals.  He also previously held positions of increasing responsibility at Breakaway Technologies, Pharmacia, Novartis and Bristol-Myers Squibb Company.  Mr. Rowland holds a Bachelors of Science in accounting from St. Joseph's University, and a Master of Business Administration degree from the Rutgers University.

Michael S. Wyzga has served as a director and the Chairman of the Audit Committee since March 2012. Mr. Wyzga is the former President and Chief Executive Officer of Radius Health, Inc. Prior to joining Radius, Mr. Wyzga was Executive Vice President, Finance and Chief Financial Officer of Genzyme until its acquisition by Sanofi in April 2011. Mr. Wyzga joined Genzyme in 1998 and held primary responsibility for the firm's financial management worldwide. He provided key leadership in the successful $20.1 billion sale of Genzyme to Sanofi, which was the second-largest acquisition in biotechnology history. Prior to joining Genzyme, Mr. Wyzga was Chief Financial Officer of Sovereign Hill Software. He previously served as Vice President of Finance and Chief Financial Officer of CacheLink Corporation, a client/service software company. Mr. Wyzga also held management positions at Lotus Development Corporation and Digital Equipment Corporation. He received an MBA from Providence College and a BS from Suffolk University.

Member of the Compensation Committee

Stock transaction information provided by EDGAR Online. Idenix Pharmaceuticals, Inc. makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.